Patents by Inventor Tomá Sobrino Moreiras

Tomá Sobrino Moreiras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers for Diagnosis and Prognosis of Corneal Ectatic Disorders
    Publication number: 20210132084
    Abstract: The invention relates to the field of the diagnosis and prognosis methods of molecular pathologies. In particular, the invention relates to methods for determining the diagnosis of an ectatic disease of the cornea in a subject, for determining the risk of developing an ectatic disease of the cornea in a subject, for determining the clinical outcome of a subject suffering from an ectatic disease of the cornea and for selecting a subject to be treated with a therapy for an ectatic disease of the cornea based on the determination of the expression levels of TLR2 and/or TLR4 markers. The invention also relates to the use of the TLR2 and/or TLR4 as diagnosis and prognosis markers for an ectatic disease of the cornea.
    Type: Application
    Filed: January 11, 2021
    Publication date: May 6, 2021
    Inventors: Maria Isabel Lema Gesto, José Antonio Castillo Sánchez, Tomás Sobrino Moreiras, Francisco Campos Perez
  • Biomarkers for diagnosis and prognosis of corneal ectatic disorders
    Patent number: 10914746
    Abstract: The invention relates to the field of the diagnosis and prognosis methods of molecular pathologies. In particular, the invention relates to methods for determining the diagnosis of an ectatic disease of the cornea in a subject, for determining the risk of developing an ectatic disease of the cornea in a subject, for determining the clinical outcome of a subject suffering from an ectatic disease of the cornea and for selecting a subject to be treated with a therapy for an ectatic disease of the cornea based on the determination of the expression levels of TLR2 and/or TLR4 markers. The invention also relates to the use of the TLR2 and/or TLR4 as diagnosis and prognosis markers for an ectatic disease of the cornea.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 9, 2021
    Assignees: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, SERVIZO GALEGO DE SAUDE (SERGAS)
    Inventors: María Isabel Lema Gesto, José Antonio Castillo Sánchez, Tomás Sobrino Moreiras, Francisco Campos Perez
  • RIBOFLAVIN FOR THE TREATMENT OF ISCHEMIC STROKE AND/OR OTHER GLUTAMATE EXCITOTOXICITY-ASSOCIATED DISEASES
    Publication number: 20180153897
    Abstract: The present invention relates to a combination therapy comprising the use of riboflavin and oxaloacetate. Specifically, it is directed to new compositions, pharmaceutical compositions, kits of parts and methods for treating ischemic stroke and/or other excitotoxicity-associated diseases. It further relates to riboflavin for use in the therapeutic treatment of acute ischemic stroke by intravascular administration within the first twelve hours of symptom onset.
    Type: Application
    Filed: May 4, 2016
    Publication date: June 7, 2018
    Inventors: José Manuel BREA FLORIANI, Francisco CAMPOS PÉREZ, José CASTILLO SÁNCHEZ, Mª Isabel LOZA GARCÍA, Tomás SOBRINO MOREIRAS
  • BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS OF CORNEAL ECTATIC DISORDERS
    Publication number: 20180067128
    Abstract: The invention relates to the field of the diagnosis and prognosis methods of molecular pathologies. In particular, the invention relates to methods for determining the diagnosis of an ectatic disease of the cornea in a subject, for determining the risk of developing an ectatic disease of the cornea in a subject, for determining the clinical outcome of a subject suffering from an ectatic disease of the cornea and for selecting a subject to be treated with a therapy for an ectatic disease of the cornea based on the determination of the expression levels of TLR2 and/or TLR4 markers. The invention also relates to the use of the TLR2 and/or TLR4 as diagnosis and prognosis markers for an ectatic disease of the cornea.
    Type: Application
    Filed: February 16, 2016
    Publication date: March 8, 2018
    Inventors: María Isabel Lema Gesto, José Antonio Castillo Sánchez, Tomás Sobrino Moreiras, Francisco Campos Perez
  • USE OF OXALOACETATE IN THE TREATMENT OF ISCHAEMIA
    Publication number: 20130131178
    Abstract: The invention relates to the use of oxaloacetate in the treatment of ischaemia. The invention provides quantities that are therapeutically effective for the treatment of disorders associated with high levels of glutamate in brain tissue, such as, for example, cerebral ischaemia. In addition, the compositions of the invention are suitable for bolus-type delivery.
    Type: Application
    Filed: May 13, 2011
    Publication date: May 23, 2013
    Applicants: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, HOSPITALARIO UNIVERSITARIO DE SANTIAGO (IDICHUS), SERVIZO GALEGO DE SAUDE (SERGAS)
    Inventors: José Castillo Sánchez, Tomá Sobrino Moreiras, Pedro Ramos Cabrer, Francisco Campos Perez, Jesús Agulla Freire, Bárbara Argibay González